<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03046355</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-16-1053</org_study_id>
    <nct_id>NCT03046355</nct_id>
  </id_info>
  <brief_title>Timing of Delivery in Fetal Growth Restriction of Uncomplicated Women</brief_title>
  <acronym>GROW</acronym>
  <official_title>Timing of Delivery in Fetal Growth Restriction of Uncomplicated Women: A Randomized Controlled Trial (GROW Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the study is to determine whether labor induction at 37 weeks of pregnancy can
      improve the baby's health at birth when compared with delivery at a later point in the
      pregnancy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 13, 2017</start_date>
  <completion_date type="Anticipated">September 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of children with birthweight less than the third percentile for gestational as assessed by NICHD nomograms</measure>
    <time_frame>Immediately at birth</time_frame>
    <description>NICHD is National Institute of Child Health and Human Development The NICHD nomogram will indicate their birth weight percentile based on their gestational age and ethnicity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of children presenting with CNM</measure>
    <time_frame>Up to 6 weeks after delivery</time_frame>
    <description>Composite neo-natal morbidity (CNM) is any of the following: Apgar score &lt;5 at 5 minutes, seizure, sepsis, hypoglycemia requiring intravenous treatment, mechanical ventilation, CPAP (continuous positive airway pressure) or high-flow nasal cannula for &gt;2 hours, oxygen supplementation with FiO2 (fraction of inspired oxygen) &gt;30% for &gt;4 hours, death before discharge or IUFD (intrauterine fetal death).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of women presenting with CMM</measure>
    <time_frame>Up to 6 weeks after delivery</time_frame>
    <description>Composite maternal morbidity (CMM) is any of the following: chorioamnionitis, transfusion of blood products, endometritis, wound infection or separation, deep venous thrombosis, pulmonary embolism, admission to the intensive care unit, or death. Rates of cesarean section as well as indications in each group will also be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of children delivered by cesarean section</measure>
    <time_frame>Immediately at birth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of children admitted to NICU</measure>
    <time_frame>Up to 6 weeks after delivery</time_frame>
    <description>NICU is neo-natal intensive care unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of children presenting with SGA</measure>
    <time_frame>Immediately at birth</time_frame>
    <description>SGA is small for gestational age when birthweight &lt;10% for gestational age</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Fetal Growth Restriction</condition>
  <arm_group>
    <arm_group_label>Labor induction at 37.0 to 37.6 weeks of gestation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diagnosis of FGR with induction at 37 weeks 0 days of gestation to 37 weeks and 6 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expectant monitoring until delivery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Diagnosis of FGR managed with expectant monitoring and delivery as indicated</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Labor induction at 37.0 to 37.6 weeks of gestation</intervention_name>
    <description>Diagnosis of FGR with induction at 37 weeks 0 days of gestation to 37 weeks and 6 days</description>
    <arm_group_label>Labor induction at 37.0 to 37.6 weeks of gestation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Expectant monitoring until delivery</intervention_name>
    <description>Diagnosis of FGR managed with expectant monitoring and delivery as indicated</description>
    <arm_group_label>Expectant monitoring until delivery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Singleton pregnancy

          -  Gestational age 34 weeks 0 days to 37 weeks 0 days at time of enrollment

          -  Dating of pregnancy by last menstrual period consistent with an ultrasound, ultrasound
             &lt;21 weeks and 6 days of gestation, or known date of conception in the setting of in
             vitro fertilization

          -  No known major anomalies (anomalies requiring surgery antenatally or in the neonatal
             period, anomalies not compatible with life as determined by the physician)

          -  FGR defined as estimated fetal weight (EFW) &lt; 10th percentile by Hadlock formula with
             normal umbilical artery Doppler studies and normal amniotic fluid

        Exclusion Criteria:

          -  Known major fetal anomalies

          -  Multiple gestation or selective reduction of multiple gestation after 14 weeks

          -  Previous stillbirth at term

          -  Indications for delivery at &lt;39 weeks. Common examples include:

          -  Placenta previa

          -  Placenta accreta

          -  Vasa previa

          -  History of classical cesarean section or myomectomy

          -  Human immunodeficiency virus (HIV)

          -  Oligohydramnios (low amniotic fluid, defined as maximum vertical pocket &lt;2.0cm)

          -  High-risk pregnancy as determined by the physician. Common examples include:

          -  Pre-gestational diabetes or gestational diabetes on medication

          -  Chronic hypertension on medication

          -  Maternal cardiac disease

          -  Asthma requiring oral steroids during pregnancy

          -  Chronic renal disease

          -  Antiphospholipid syndrome

          -  Hyperthyroidism

          -  Prior stillbirth

          -  Systemic lupus erythematous

          -  Hemoglobinopathies such as sickle cell disease
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Pregnant women</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Baha M Sibai, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Baha M Sibai, MD</last_name>
    <phone>(713) 500-6421</phone>
    <email>Baha.M.Sibai@uth.tmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mallory M Hoffman, MD</last_name>
    <phone>(713) 500-6421</phone>
    <email>Mallory.M.Hoffman@uth.tmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Hermann Memorial City Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Baha Sibai, MD</last_name>
      <phone>713-500-6421</phone>
      <email>baha.m.sibai@uth.tmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Baha M Sibai, MD</last_name>
      <phone>713-500-6421</phone>
      <email>Baha.M.Sibai@uth.tmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bellaire - Memorial Hermann</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Baha M Sibai, MD</last_name>
      <phone>713-500-6421</phone>
      <email>baha.m.sibai@uth.tmc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2017</study_first_submitted>
  <study_first_submitted_qc>February 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2017</study_first_posted>
  <last_update_submitted>July 12, 2017</last_update_submitted>
  <last_update_submitted_qc>July 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Bahaeddine M Sibai</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fetal Growth Retardation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

